Last reviewed · How we verify

NCT05870163

Post-Market Registry for the Evaluation of RefluxStop in GERD Treatment

Recruiting now Last updated 1 April 2025
What this trial tests

trial testing RefluxStop implantation in Gastroesophageal Reflux Disease (GERD) in 2,500 participants. Currently enrolling.

Timeline
20 February 2023
Primary endpoint
1 December 2025
31 December 2029

Quick facts

Lead sponsorImplantica CE Reflux Ltd.
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment2,500
Start date20 February 2023
Primary completion1 December 2025
Estimated completion31 December 2029
Sites6 locations across Italy, Switzerland, Germany, Norway

Drugs / interventions tested

Conditions studied

Sponsor

Implantica CE Reflux Ltd.

Who can join

18 and older, any sex, with Gastroesophageal Reflux Disease (GERD). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This post-market registry aims to assess safety and performance of RefluxStop™ in the treatment of Gastroesophageal Reflux Disease (GERD) in standard of care procedures.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Gastroesophageal Reflux Disease (GERD)

Currently open trials in the same condition.

Other Implantica CE Reflux Ltd. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05870163.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing